...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
【24h】

Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.

机译:3-氨基吡咯烷基喹诺酮类DC-159a和西他沙星对DNA促旋酶和拓扑异构酶IV的双重靶向特性:有助于减少耐喹诺酮类肺炎链球菌的体外出现。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: DC-159a (a novel quinolone) and sitafloxacin (DU-6859a) are structurally related quinolones, bearing a 3-aminopyrrolidyl substitution. We investigated the relationship between the target preferences of these 3-aminopyrrolidyl quinolones, in vitro potencies and emergence of quinolone-resistant mutants in Streptococcus pneumoniae, compared with other quinolones. METHODS: MICs, resistance frequencies and mutant prevention concentrations (MPCs) were determined using quinolone-susceptible strains and first-step parC mutant strains of S. pneumoniae. Target preferences were tested by the following two methods: antibacterial activities against gyrA or parC mutants and in vitro enzyme assays for the determination of 50% inhibition (IC(50)) values. RESULTS: DC-159a and sitafloxacin exhibited potent antibacterial activities, low frequencies of mutant selection, low MPCs and narrow mutant selection windows against both quinolone-susceptible strains and first-step parC mutants of S. pneumoniae, compared with gatifloxacin, moxifloxacin and other quinolones tested. DC-159a and sitafloxacin showed relatively low MIC ratios against single gyrA or parC mutants relative to the wild-type strain and low IC(50) ratios against DNA gyrase and topoisomerase IV. CONCLUSIONS: DC-159a and sitafloxacin demonstrated a more balanced dual-targeting activity than gatifloxacin, moxifloxacin and other quinolones tested. In addition, DC-159a and sitafloxacin have a lower propensity for selecting first- and second-step resistant mutants.
机译:目的:DC-159a(一种新型喹诺酮)和西他沙星(DU-6859a)是结构相关的喹诺酮,带有3-氨基吡咯烷基取代基。我们调查了这些3-氨基吡咯烷基喹诺酮的目标偏好,体外效价和肺炎链球菌与其他喹诺酮相比喹诺酮耐药突变体的出现之间的关系。方法:使用喹诺酮类易感菌株和肺炎链球菌第一步parC突变株,测定MIC,耐药频率和突变预防浓度(MPC)。通过以下两种方法测试了目标偏好:针对gyrA或parC突变体的抗菌活性以及用于测定50%抑制(IC(50))值的体外酶法。结果:与加替沙星,莫西沙星和其他喹诺酮类相比,DC-159a和西他沙星对肺炎链球菌易感菌株和第一步parC突变体均表现出强大的抗菌活性,突变选择频率低,MPC低以及突变选择窗口窄。经过测试。 DC-159a和西他沙星相对于野生型菌株对单个gyrA或parC突变体显示相对较低的MIC比,而对DNA旋转酶和拓扑异构酶IV的IC(50)比例低。结论:DC-159a和西他沙星比加替沙星,莫西沙星和其他喹诺酮类药物具有更均衡的双重靶向活性。另外,DC-159a和西他沙星具有较低的选择第一步和第二步耐药突变体的倾向。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号